These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38260271)

  • 21. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous Ultra-Sensitive Detection of Structural and Single Nucleotide Variants Using Multiplex Droplet Digital PCR in Liquid Biopsies from Children with Medulloblastoma.
    Arthur C; Jylhä C; de Ståhl TD; Shamikh A; Sandgren J; Rosenquist R; Nordenskjöld M; Harila A; Barbany G; Sandvik U; Tham E
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
    Anderson CJ; Yang H; Parsons J; Ahrens WA; Jagosky MH; Hsu JH; Patt JC; Kneisl JS; Steuerwald NM
    Clin Orthop Relat Res; 2024 Jun; 483(1):39-48. PubMed ID: 38905450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
    Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
    BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.
    Wan N; Weinberg D; Liu TY; Niehaus K; Ariazi EA; Delubac D; Kannan A; White B; Bailey M; Bertin M; Boley N; Bowen D; Cregg J; Drake AM; Ennis R; Fransen S; Gafni E; Hansen L; Liu Y; Otte GL; Pecson J; Rice B; Sanderson GE; Sharma A; St John J; Tang C; Tzou A; Young L; Putcha G; Haque IS
    BMC Cancer; 2019 Aug; 19(1):832. PubMed ID: 31443703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.
    Parsons HA; Rhoades J; Reed SC; Gydush G; Ram P; Exman P; Xiong K; Lo CC; Li T; Fleharty M; Kirkner GJ; Rotem D; Cohen O; Yu F; Fitarelli-Kiehl M; Leong KW; Hughes ME; Rosenberg SM; Collins LC; Miller KD; Blumenstiel B; Trippa L; Cibulskis C; Neuberg DS; DeFelice M; Freeman SS; Lennon NJ; Wagle N; Ha G; Stover DG; Choudhury AD; Getz G; Winer EP; Meyerson M; Lin NU; Krop I; Love JC; Makrigiorgos GM; Partridge AH; Mayer EL; Golub TR; Adalsteinsson VA
    Clin Cancer Res; 2020 Jun; 26(11):2556-2564. PubMed ID: 32170028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
    Chen X; Chang CW; Spoerke JM; Yoh KE; Kapoor V; Baudo C; Aimi J; Yu M; Liang-Chu MMY; Suttmann R; Huw LY; Gendreau S; Cummings C; Lackner MR
    Clin Cancer Res; 2019 Apr; 25(7):2254-2263. PubMed ID: 30617129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.
    Northcott J; Bartha G; Harris J; Li C; Navarro FCP; Pyke RM; Hong M; Zhang Q; Ma S; Chen TX; Lai J; Udar N; Saldivar JS; Ayash E; Anderson J; Li J; Cui T; Le T; Chow R; Velasco RJ; Mallo C; Santiago R; Bruce RC; Goodman LJ; Chen Y; Norton D; Chen RO; Lyle JM
    Oncotarget; 2024 Mar; 15():200-218. PubMed ID: 38484152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
    Álvarez N; Martín A; Dorado S; Colmenares R; Rufián L; Rodríguez M; Giménez A; Carneros L; Sanchez R; Carreño G; Rapado I; Heredia Y; Martínez-López J; Barrio S; Ayala R
    Front Immunol; 2024; 15():1252258. PubMed ID: 38938565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma.
    Fu Y; Xu Y; Liu W; Zhang J; Wang F; Jian Q; Huang G; Zou C; Xie X; Kim AH; Mathios D; Pang F; Li F; Wang K; Shen J; Yin J
    EClinicalMedicine; 2024 Jul; 73():102697. PubMed ID: 39022798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
    Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.
    Liu W; Li Y; Tang Y; Song Q; Wang J; Li N; Chen S; Shi J; Wang S; Li Y; Jiao Y; Zeng Y; Jin J
    EBioMedicine; 2022 Apr; 78():103945. PubMed ID: 35306340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
    Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
    Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents.
    Seidel MG; Kashofer K; Moser T; Thueringer A; Liegl-Atzwanger B; Leithner A; Szkandera J; Benesch M; El-Heliebi A; Heitzer E
    Front Pediatr; 2022; 10():926405. PubMed ID: 36046479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
    Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.